To explore whether DAC positively modulates the IL-33/ST2 axis in the tumor microenvironment, we assessed IL33 and ST2 expression in the TME of mice early after exposure to this epigenetic modifier drug (i.e., 3 days). Here, IL33 is linked to neoplasm.